Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials

Radiotherapy and Oncology

Volumn 82, Issue 3, 2007, Pages 247-253

  Overgaard, Marie ^a   Nielsen, Hanne M ^a,b   Overgaard, Jens ^b  

^a Department of Oncology ^*  (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Breast cancer; Positive lymph nodes; Postmastectomy radiotherapy; Randomized clinical trial

Indexed keywords

CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSENSUS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HIGH RISK PATIENT; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RADIATION DOSE; SURVIVAL RATE; SURVIVAL TIME; TREATMENT INDICATION;

ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; FEMALE; FLUOROURACIL; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MASTECTOMY; METHOTREXATE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSTOPERATIVE CARE; PROGNOSIS; SURVIVAL RATE; TAMOXIFEN;

EID: 33847617832     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2007.02.001     Document Type: Article

References (27)

1. Harris J.R., Halpin-Murphy P., McNeese M., Mendenhall N.P., Morrow M., and Robert N.J. Consensus Statement on postmastectomy radiation therapy. Int J Radiat Oncol Biol Phys 44 (1999) 989-990
2. Recht A., Edge S.B., Solin L.J., et al. American Society of Clinical Oncology. Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19 (2001) 1539-1569
3. Eifel P., Axelson J.A., Costa J., et al. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst 93 (2001) 979-989
4. Kurtz J. EUSOMA Working Party. The curative role of radiotherapy in the treatment of operable breast cancer. Eur J Cancer 38 (2002) 1961-1974
5. Goldhirsch A., Wood W.C., Gelber R.D., et al. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 21 (2003) 3357-3365
6. Truong P.T., Olivotto I.A., Whelan T.J., and Levine M. Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Clinical practice guidelines for the care and treatment of breast cancer: 16. Locoregional post-mastectomy radiotherapy. CMAJ 170 (2004) 1263-1273
7. Goldhirsch A., Glick J.H., Gelber R.D., Coates A.S., Thurlimann B., and Senn H.J. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 16 (2005) 1569-1583
8. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;366:2087-106.
9. Overgaard M., Hansen P.S., Overgaard J., et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 337 (1997) 949-955
10. Overgaard M., Jensen M.B., Overgaard J., et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet 353 (1999) 1641-1648
11. Overgaard M., Nielsen H.M., and Overgaard J. Is the benefit of postmastectomy irradiation limited to patients with 4 or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b & c randomized trials. Radiother Oncol 73 Suppl. 1 (2004) S14-S15
12. Nielsen H.M., Overgaard J., Grau C., Christensen J.J., and Overgaard M. Audit of the radiotherapy in the DBCG 82 b&c trials - a validation study of the 1,538 patients randomised to postmastectomy radiotherapy. Radiother Oncol 76 (2005) 285-292
13. Højris I., Overgaard M., Christensen J.J., and Overgaard J. Morbidity and mortality of ischaemic heart disease in high-risk breast-cancer patients after adjuvant postmastectomy systemic treatment with or without radiotherapy: analysis of DBCG 82b and 82c randomised trials. Lancet 354 (1999) 1425-1430
14. Nielsen H.M., Overgaard M., Grau C., Jensen A.R., and Overgaard J. Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: long-term results from the Danish Breast Cancer Cooperative Group DBCG 82 b and c randomized studies. J Clin Oncol 24 (2006) 2268-2275
15. Nielsen H.M., Overgaard M., Grau C., Jensen A.R., and Overgaard J. Loco-regional recurrence after mastectomy in high-risk breast cancer-risk and prognosis. An analysis of patients from the DBCG 82 b&c randomization trials. Radiother Oncol 79 (2006) 147-155
16. Gelman R., Gelber R., Henderson I.C., Coleman C.N., and Harris J.R. Improved methodology for analyzing local and distant recurrence. J Clin Oncol 8 (1990) 548-555
17. Greenhalgh T. How to read a paper. Statistics for the non-statistician. II: "Significant" relations and their pitfalls. BMJ 315 (1997) 422-425
18. Overgaard J., and Bartelink H. Breast cancer survival advantage with radiotherapy. Lancet 356 (2000) 1269-1270
19. Overgaard M. Radiotherapy as part of a multidisciplinary treatment strategy in early breast cancer. Eur J Cancer 37 (2001) S33-S43
20. Ragaz J., Olivotto I.A., Spinelli J.J., et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst 97 (2005) 116-126
21. Whelan T., and Levine M. More evidence that locoregional radiation therapy improves survival: what should we do?. J Natl Cancer Inst 97 (2005) 82-84
22. Koscielny S., Tubiana M., Le M.G., et al. Breast cancer: relationship between the size of the primary tumour and the probability of metastatic dissemination. Br J Cancer 49 (1984) 709-715
23. Højris I., Andersen J., Overgaard M., and Overgaard J. Late treatment-related morbidity in breast cancer patients randomized to postmastectomy radiotherapy and systemic treatment versus systemic treatment alone. Acta Oncol 39 (2000) 355-372
24. Poortmans P.M., Venselaar J.L., Struikmans H., et al. The potential impact of treatment variations on the results of radiotherapy of the internal mammary lymph node chain: a quality-assurance report on the dummy run of EORTC Phase III randomized trial 22922/10925 in Stage I-III breast cancer(1). Int J Radiat Oncol Biol Phys (2001) 491399-491408
25. Sotiriou C., Wirapati P., Loi S., et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98 (2006) 262-272
26. Kreike B., Halfwerk H., Kristel P., et al. Gene expression profiles of primary breast carcinomas from patients at high risk for local recurrence after breast-conserving therapy. Clin Cancer Res 12 (2006) 5705-5712
27. Cheng S.H., Horng C.F., West M., et al. Genomic prediction of locoregional recurrence after mastectomy in breast cancer. J Clin Oncol 24 (2006) 4594-4602